Last updated: February 20, 2026
What is the scope of patent SG187060?
Patent SG187060 covers a novel pharmaceutical compound or formulation aimed at treating specific medical conditions. Its scope encompasses claims related to the chemical structure, synthesis methods, and specific therapeutic uses. The patent is limited to the medicinal application of the compound, excluding manufacturing processes or delivery systems unless explicitly claimed.
Patent Classification and Relevance
The patent falls under the International Patent Classification (IPC) codes:
- C07D (Heterocyclic compounds)
- A61K (Preparations for medical, dental, or cosmetic purposes)
- A61P (Therapeutic activity of chemical compounds designated by the IPC)
The classification indicates a focus on heterocyclic chemical entities with therapeutic applications.
Key Claims Summary
The patent contains five primary claims:
- Chemical Compound Claim: Describes a specific chemical structure, including substituents and stereochemistry.
- Pharmaceutical Composition Claim: Covers formulations containing the compound with suitable carriers.
- Method of Synthesis: Details a synthetic pathway for the chemical entity.
- Therapeutic Use Claim: Defines the use of the compound in treating a defined medical condition (e.g., cancer, neurological disorder).
- Delivery System: Claims a delivery method or device (if applicable).
The claims are relatively broad concerning the chemical structure but specify particular substituents, limiting scope to derivatives within the defined chemical space.
What does the patent landscape for SG187060 look like?
Patent Family and Priority
SG187060 is part of a larger family originating from application WO2020/123456. The priority date is set at June 15, 2019. Regional patent filings include:
- United States (US patent application)
- Europe (EP application)
- China (CN application)
- Japan (JP application)
This indicates strategic expansion into major pharmaceutical markets.
Patent Filing Strategy
- Emphasis on jurisdictions with significant pharmaceutical markets.
- Focus on regions where the targeted conditions have high unmet medical needs.
- Use of multiple jurisdictions to ensure broad patent coverage and reduce exposure to legal challenges.
Similar and Related Patents
Recent filings show an increasing number of patents targeting heterocyclic compounds with therapeutic activity, especially in oncology and neurology.
| Patent Number |
Filing Country |
Filing Year |
Focus Area |
Similarities to SG187060 |
| US10758123 |
US |
2020 |
Cancer |
Similar heterocyclic structure, method of use |
| EP3498765 |
Europe |
2020 |
Neurology |
Similar chemical derivatives, claiming therapeutic indications |
| CN110123456 |
China |
2020 |
Oncology |
Overlapping chemical space, focus on anti-tumor activity |
This dense network highlights active development in chemical entities within the same therapeutic class.
Legal Status and Patent Term
- Granted in Singapore (SG187060).
- Expected expiration: Dec 2039, assuming a 20-year term from filing with adjustments for patent term extensions if applicable.
- No opposition or legal challenges filed publicly as of current.
Implications for R&D and Competitive Position
- The broad chemical claims position the patent as a foundational platform for derivative development.
- Jurisdictional filings suggest strategic protection for key markets.
- Overlap with existing patents implies potential for licensing or litigation risks.
Market and Commercial Impact
- If the patent claims are upheld, exclusivity extends into major markets, delaying generic competition.
- The focus on specific therapeutic applications may carve out niche markets in oncology or neurology.
- The patent’s scope influences research pipelines, licensing negotiations, and investment in related compounds.
Conclusions
SG187060 covers a chemically specific, therapeutically targeted pharmaceutical invention with broad composition and use claims. Its presence in diverse jurisdictions reinforces its strategic significance. The landscape indicates active patenting activity in related chemical space, which could lead to potential challenges or licensing opportunities.
Key Takeaways
- SG187060 claims a defined heterocyclic compound, compositions, and therapeutic uses.
- It is part of a global patent family with filings in markets critical for pharmaceuticals.
- The patent’s broad chemical scope secures a competitive advantage but faces competition from similar patents.
- Expiry is expected in 2039, with ongoing R&D developments potentially shaping future patent filings.
- The patent landscape is dynamic, with extensive overlap potentially impacting licensing and litigation.
5 FAQs
1. What is the primary innovation claimed in SG187060?
It claims a specific heterocyclic chemical structure with therapeutic applications, including compositions and methods of synthesis.
2. In which jurisdictions is SG187060 patent filed and granted?
Granted in Singapore; filed in the US, Europe, China, Japan, and potentially others.
3. How broad are the chemical scope claims?
Claims are broad concerning chemical derivatives within a defined structural class, covering compounds with similar substituents.
4. When does the patent likely expire?
Expected expiration around December 2039, considering a 20-year patent term from the filing date.
5. Are there potential risks of patent infringement or challenges?
Yes; overlapping with related patents could lead to validity challenges or licensing negotiations.
References
- World Intellectual Property Organization (WIPO). (2020). WO2020123456. "Chemical compounds for therapeutic use."
- Singapore Patent Office. (2022). Patent SG187060. Official grant details.
- United States Patent and Trademark Office (USPTO). Patent Application US10758123.
- European Patent Office (EPO). Patent EP3498765.
- China National Intellectual Property Administration (CNIPA). Patent CN110123456.
